Relmada Therapeutics, Inc.

US$3.90As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:RLMDHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (1.63%)
Div yield —
ROE (55.66%)
Biotechnology
Beta (5Y) 0.57
PE TTM —
TSR TTM 72.57%
Mkt cap US$416.0M
ROIC (34.96%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$4.91
25.86%
(3.52%)
Hold 10|1|2|1|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.05
0.05
0.05
0.05
12.81%
10.64%
0.54%
(2.39%)
Revenue$M
24.87
25.13
24.61
24.63
(2.32%)
1.27%
(2.58%)
(2.40%)
Peers (US$416.0M)
Cap (US$)
PE
414.7M
2.554x
419.8M
—
Capital
TTM
5Y
10Y
Leveragex
0.515
0.014
0.020
EBIT/Intx
0.245
0.200
0.227
Own earn%
70.09
(3.26)
(4.96)
Sh yield%
41.83
51.40
50.40
Owners
Insiders/Inst%
5.54
43.25
Short interest%
0.92
SBC / revenue%
3.49
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
1–8
$1 testx
0.1
Incr. ROIC%
1